Merck Serono to Broaden Its General Medicines Portfolio in Emerging Markets with Affordable, High-Quality Medicines
Business Wire - 1 hr 14 mins ago
--Lupin will provide product dossiers and supply finished products for portfolio expansion
Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis
Business Wire - Mon Sep 15, 12:30PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced data from the pivotal Phase 3 fracture outcomes study for odanacatib in postmenopausal women with osteoporosis. Odanacatib is Merck's investigational once-weekly cathepsin K inhibitor. In the Long-Term Odanacatib Fracture Trial (LOFT), odanacatib met its primary endpoints and significantly reduced the risk of osteoporotic hip, spine and non-vertebral fractures compared with placebo. The results from this trial were presented today at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting in Houston, Texas.
New Product Launch, Accelerated Drug Approvals, Study Initiation, and Market Activity - Research Reports on Johnson & Johnson, Merck, Medtronic, Pharmacyclics and NPS Pharma
PR Newswire - Mon Sep 15, 8:15AM CDT
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Medtronic, Inc. (NYSE: MDT), Pharmacyclics Inc. (NASDAQ: PCYC) and NPS Pharmaceuticals, Inc. (NASDAQ: NPSP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6464-100free.
BeiGene Receives Clinical Milestone Payment for Development of BGB-290
Business Wire - Mon Sep 15, 7:00AM CDT
BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-290, an investigational poly (ADP-ribose) polymerase (PARP) inhibitor candidate currently in Phase 1 development. The milestone triggers a US$ 9 million payment from Merck to BeiGene.
Merck Millipore Recognized for Technologically Advanced Products by R&D Magazine
Business Wire - Mon Sep 15, 1:00AM CDT
Merck Millipore, the Life Science division of Merck, announced it has received two R&D Magazine 100 Awards for innovative products released to market in 2014. The 52nd Annual R&D Awards recognize the 100 most technologically significant products introduced into the marketplace over the past year.
Trading Guidelines for J&J, Merck, Pfizer, 8 Other Drug Companies
at The Street - Fri Sep 12, 10:32AM CDT
Here are some numbers to help investors make prudent decisions when allocating cash to 11 big-cap pharmaceutical companies.
Dow 30 Stock Roundup: Boeing Bags $11B Order, GE to Sell Appliance Unit to Electrolux - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Sep 12, 9:50AM CDT
The Dow had a dismal week as energy prices continued to dominate proceedings.
Research and Markets: Global Asthma Market 2014-2018: Leading Vendors are AstraZeneca, F. Hoffmann-La Roche, GSK, Merck & Novartis
Business Wire - Fri Sep 12, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/572r9k/global_asthma) has announced the addition of the "Global Asthma Market 2014-2018" report to their offering.
Merck Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer
PR Newswire Europe - Fri Sep 12, 9:08AM CDT
DARMSTADT, Germany, September 12, 2014 /PRNewswire/ --
Global Animal Health Market 2014-2018: Key Vendors are Bayer, Elanco, Merck Animal Health, Merial and Zoetis
PR Newswire Europe - Fri Sep 12, 7:02AM CDT
DUBLIN, Sept. 12, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/jr5z25/global_animal] has announced the addition of the "Global Animal Health Market 2014-2018" [http://www.researchandmarkets.com/research/jr5z25/global_animal] report to their offering.
Global Asthma Market 2014-2018: Leading Vendors are AstraZeneca, F. Hoffmann-La Roche, GSK, Merck & Novartis
M2 - Fri Sep 12, 6:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/69j7kn/global_asthma) has announced the addition of the "Global Asthma Market 2014-2018" report to their offering. The Global Asthma Market to grow at a CAGR of 4.5% over the period 2013-2018. One trend emerging in this market is the use of combination therapies for the treatment of asthma patients. These therapies can improve patient condition in persistent asthma and act via reduction of the symptoms by controlling inflammation in the respiratory tract. According to the report, the major driving factor of this market is a rise in the prevalence of environmental pollution. Globalization and urbanization coupled with industrialization lead to an increase in environmental pollution. Further, the report states that the unknown etiology of the disease is a major challenge to the market which makes it difficult for drug manufacturers to develop a remedy. The underlying causes of asthma are not completely understood, though allergens and pollutants worsen the condition of the patient. This report covers the present scenario and the growth prospects of the Global Asthma market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various class of drugs used in the treatment of asthma: - Bronchodilators - Leukotriene antagonists - Mast cell stabilizers - Immunosuppressants Key Vendors - AstraZeneca - F. Hoffmann-La Roche - GlaxoSmithKline - Merck - Novartis Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Class of Drugs - Global Bronchodilators Market - Global Leukotriene Antagonists Market - Global Mast Cell Stabilizers Market - Global Immunosuppressants Market - Global Combination of ICS/LABA Market - Global Other Asthma Drugs Market - Geographical Segmentation - Rate of Incidence and Prevalence - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Pipeline Portfolio - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/69...bal_asthma
Global Animal Vaccines Market 2014-2018: Leading Vendors are Bayer HealthCare, Elanco Animal Health, Merck Animal Health, Novartis Animal Health, Sanofi & Zoetis
M2 - Fri Sep 12, 6:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/56q7l6/global_animal) has announced the addition of the "Global Animal Vaccines Market 2014-2018" report to their offering. The Global Animal Vaccines market to grow at a CAGR of 8.25% over the period 2013-2018 This report covers the present scenario and the growth prospects of the Global Animal Vaccines market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various animal vaccines. In terms of vaccines types, the Global Animal Vaccines market can be segmented into six: Companion Animal Vaccines, Livestock Vaccines, Porcine Vaccines, Poultry Vaccines, Equine Vaccines, and Other Animal Vaccines. One of the major emerging trends in this market is an increase in acquisitions. Vendors have been focusing on acquisitions to increase their foothold in the market through increased investments. According to the report, one of the main drivers of this market is an increase in the prevalence of animal diseases worldwide, in both developed and developing countries. As a result, the use of animal vaccines has increased. The increasing susceptibility of animals to chronic diseases has driven the revenue growth of this market to a great extent. Further, the report states that one of the main challenges that the market faces is a rise in the maintenance costs of vaccines. Though the animal vaccines have numerous benefits, the high cost of these vaccines hinders acceptability among end-users. Key Vendors - Bayer HealthCare - Elanco Animal Health - Merck Animal Health - Novartis Animal Health - Sanofi - Zoetis Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Products - Market Segmentation by Technology - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/56...bal_animal
Global Moderate Psoriasis Therapeutics Pipeline Report 2014 - 17 Companies & 23 Drug Profiles
M2 - Fri Sep 12, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jn2cxm/moderate) has announced the addition of the "Moderate Psoriasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Johnson & Johnson - Boehringer Ingelheim GmbH - Amgen Inc. - Eli Lilly and Company - Merck & Co., Inc. - AbGenomics International, Inc. - ApoPharma Inc. - Novartis AG - Pfizer Inc. - OPKO Health, Inc. - Idera Pharmaceuticals, Inc. - Almirall, S.A. - Syntrix Biosystems, Inc. - Vascular Biogenics Ltd. - Hy BioPharma Inc. - GlycoMar Limited - Convoy Therapeutics, Inc. Drug Profiles - brodalumab - ixekizumab - secukinumab - tildrakizumab - LAS-41008 - adalimumab biosimilar - baricitinib - AbGn-168H - VB-201 - lunacalcipol - aminopterin sodium - HBP-347 - orilotimod - BI-655066 - IMO-8400 - PF-04965842 - MOL-4249 - AVX-001 - AMG-811 - guselkumab - AKP-11 - cyclosporine - GLY-2028 For more information visit http://www.researchandmarkets.com/research/jn2cxm/moderate
Merck Falls 1.09% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Sep 11, 3:39PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $59.81 to a high of $60.44. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $60.35 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
After Yesterday's Decline of 1.09%, Merck Offers Investors Better Value
Comtex SmarTrend(R) - Thu Sep 11, 3:39PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $59.81 to a high of $60.44. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $60.35 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
U.S. Northeast Remains Life-Science Darling, Attracting $8 Billion in Capital Investment, an Industrial Info News Alert
Marketwire - Thu Sep 11, 5:31AM CDT
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Like any long-term union, the one shared between the U.S. Northeast region, which comprises Delaware, New Jersey, New York and Pennsylvania, and the Life Science Industry is a classic example of a love/hate relationship. The Northeast region has been pummeled over the past few years with scores of pharmaceutical plants closing and lucrative jobs lost. On the other hand, the region remains a favorite for capital investment from both the private and public sectors for new and upgraded life-science manufacturing plants and research centers. Currently, there are 147 active reported projects translating to a hefty $7.8 billion in total investment value.
Global Migraine Drug Forecast and Market Analysis to 2023 - A Potential $3.7 Billion Market
M2 - Thu Sep 11, 4:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5qmmg2/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023" report to their offering. The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile. Key Findings - The main driver of the expansion of the migraine market will be the continuous use of Botox for chronic migraine. The introduction of reformulations of mature products as well as new classes of therapies will further increase the market size. - The biggest barrier for the introduction of new therapies will be patent expirations of the majority of the drugs marketed for migraine, which have resulted in an increase of generics, and which may negatively impact revenue from branded drugs that are expected to launch in the forecast period. - The concerns of reducing healthcare costs as part of government austerity measures, particularly in Europe, which will impede market growth. To ensure reimbursement companies will have to work closely together with payers and price their drugs competitively. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - GlaxoSmithKline - AstraZeneca - Merck - Vernalis - Almirall - Pfizer - Zogenix - NuPathe - Allergan - RedHill Biopharma - OptiNose - CoLucid Pharmaceuticals - SUDA - Revance Therapeutics - NeurAxon For more information visit http://www.researchandmarkets.com/research/5q...harmapoint
Ligand Inks 2nd Captisol Deal with CURx Pharmaceuticals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 4:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) entered into a licensing deal with CURx Pharmaceuticals, under which the former's Captisol-enabled lamotrigine program will be developed and commercialized.
Pipeline Analysis of Hospital Acquired Pneumonia Drugs 2014-2020: Tedizolid Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, Amikacin Inhale, Plazomicin, and Synflorix
M2 - Wed Sep 10, 10:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r49n8b/pipeline_analysis) has announced the addition of the "Pipeline Analysis of Hospital Acquired Pneumonia Drugs - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Nosocomial or hospital acquired infections have created numerous complications for patients in hospitals throughout the world, as these infections are caused by multidrug resistant microorganisms, the recuperation of a patient is drastically reduced and accompanied by several comorbidities. Being multidrug resistant, these organisms are immune to the conventional antibiotics hence difficult to treat. Pneumonia is one of the prominent infections caused in hospital premises. Cases of hospital acquired pneumonia are common in immunocompromised patients, post surgical infections, enteral feeding, elderly and infant patients. As hospital acquired pneumonia is mainly caused as a result of prolonged exposure to ventilator air, it is also called as ventilator associated pneumonia. Major causative pathogens include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Respiratory Syncytial Virus (RSV) has also been found to be a major causative agent of nosocomial pneumonia in new borne. Currently there are four drugs authorized for treatment of hospital acquired pneumonia; these include Zosyn (piperacillin/tazobactam), Zyvox (linezolid), Tygacil (tigecycline), and Vibativ (telavancin). Consistent research and development is being conducted in view of introducing more effective treatment options. There are five investigational drugs and one vaccine in stage III clinical trials, while ten other candidates in early stage, which mainly include biological drugs. Tedizolid phosphate and ceftolozane/tazobactam by Cubist Pharmaceutical, ceftazidime/avibactam by AstraZeneca PLC, amikacin inhale by Bayer Healthcare, plazomicin by Achaogen, Inc. and Synflorix by GlaxoSmithKline are the phase III candidates. Considering the antibacterial efficiency, and current market competition, tedizolid phosphate is expected to be the most preferred drug for treatment of nosocomial pneumonia. Amikacin inhale, an aerosolized drug is intended for sale as a drug device combination. Majority of the drugs in the late stages are biological drugs. Aridis Pharmaceutical holds four investigational drugs against various causative agents of hospital acquired pneumonia, each being monoclonal antibody therapy. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market overview Chapter 4 Hospital Acquired Pneumonia, Pipeline Analysis Chapter 5 Global Pipeline Review of Hospital Acquired Pneumonia Drugs Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Valneva SE - Achaogen, Inc. - Aridis Pharmaceuticals - AstraZeneca plc - Cubist Pharmaceuticals, Inc. - GlaxoSmithKline, Inc. - Meiji Seika Pharma Co. Ltd. - Merck & Co. Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/r4...e_analysis